Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Revenue (2016 - 2025)

Standard Biotools (LAB) has disclosed Revenue for 16 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 43.31% to -$1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $169.7 million, a 79.77% increase, with the full-year FY2024 number at $174.4 million, up 64.03% from a year prior.
  • Revenue was -$1.0 million for Q3 2025 at Standard Biotools, down from $21.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $108.2 million in Q4 2024 to a low of -$1.8 million in Q3 2024.
  • A 5-year average of $30.0 million and a median of $27.0 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 957.87% in 2021, then crashed 107.1% in 2024.
  • Standard Biotools' Revenue stood at $38.3 million in 2021, then dropped by 29.38% to $27.0 million in 2022, then increased by 4.32% to $28.2 million in 2023, then soared by 283.85% to $108.2 million in 2024, then tumbled by 100.94% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Revenue are -$1.0 million (Q3 2025), $21.8 million (Q2 2025), and $40.8 million (Q1 2025).